Novartis ESMO Event Presentation

ARDT NON-Crossover ARDT Crossover ARPI patients who crossed over to Pluvicto had a survival benefit over ARPI patients who did not cross over ARPI crossover patients (n=123) rPFS time OS time from rPD 0 10 12 14 16 22 24 Months ARPI non-crossover patients (n=111) Estimated OS probability at 12 months: 92.1% for pts randomized to ARPI arm who crossed over 68.6% for pts randomized to ARPI arm who did not cross over 0 2 8 10 12 Months 14 16 18 20 22 24 22 22 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation